GKWIM
SIOX

Gerber Kawasaki Wealth & Investment Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5
Closed – – 1218
2021
Q3 		$0 Buy
+5
New +$11 ﹤0.01% 1263

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's SIOX Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 5 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in SIOX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 5 Sio Gene Therapies Inc. Common Stock shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Sio Gene Therapies Inc. Common Stock position peaked at $0 in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.